Lenalidomide and Obinutuzumab With Chop for Newly Diagnosed Diffuse Large B-Cell Lymphoma: Phase I/Ii Results

Hematological Oncology - United Kingdom
doi 10.1002/hon.2438_138
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Decitabine Plus R-Chop in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma: Interim Results of a Phase I/Ii Study

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Rituximab, Lenalidomide, and Ibrutinib Alone and Combined With Chemotherapy for Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Smart Start: Rituximab, Lenalidomide, and Ibrutinib Alone Prior to Combination With Chemotherapy for Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Phase Ii Study of Durvalumab (Anti-Pd-L1) Combined With Either R-Chop or Lenalidomide and R-Chop in Previously Untreated, High-Risk Diffuse Large B-Cell Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Addition of Lenalidomide to R-Chop (R2chop) Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma (Dlbcl): First Report of Ecog-Acrin1412 a Randomized Phase 2 Us Intergroup Study of R2chop vs R-Chop

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Hypogammaglobulinemia and Hypocomplementemia as Strong Prognostic Factors in Newly Diagnosed Diffuse Large B Cell Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

ROBUST: First Report of Phase III Randomized Study of Lenalidomide/R-Chop (R2 -CHOP) vs Placebo/R-Chop in Previously Untreated ABC-type Diffuse Large B-Cell Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Robust: Phase Iii Randomized Study of Lenalidomide/R-Chop vs Placebo/R-Chop in Untreated Abc-Type Diffuse Large B-Cell Lymphoma and Feasibility of Cell of Origin Subtyping

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

A Phase Ii Study of Lenalidomide and Rituximab (R²) Combination in Patients With High-Risk Refractory/Relapsed Diffuse Large B-Cell Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy